Starving cancer of cholesterol: new combo shows promise in early trial
NCT ID NCT04862260
First seen Mar 29, 2026 · Last updated May 21, 2026 · Updated 7 times
Summary
This study tests whether adding three cholesterol-lowering drugs (atorvastatin, ezetimibe, and evolocumab) to standard chemotherapy can slow or stop pancreatic cancer growth. It involves 3 adults with newly diagnosed advanced or metastatic pancreatic cancer. The goal is to see if this approach is safe and feasible, and whether cutting off cholesterol supply makes cancer cells more vulnerable to treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU de Québec-Université Laval
Québec, Quebec, G1R 2J6, Canada
-
CHUM
Montreal, Quebec, H2X 0A9, Canada
Conditions
Explore the condition pages connected to this study.